Senti Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Senti Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 20, 2025 |
| FY2024 | Dec 31, 2023 | $2.56M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.29M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.76M | Mar 22, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.98M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.29M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.29M | Mar 22, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($61.44M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($52.79M) | Mar 27, 2026 |
| FY2023 | Dec 31, 2023 | ($71.06M) | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | ($58.21M) | Mar 21, 2024 |
| FY2021 | Dec 31, 2021 | ($3.86M) | Mar 7, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.78M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($61.04M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($92.73M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($62.08M) | Mar 21, 2024 |
| FY2021 | Dec 31, 2021 | ($3.87M) | Mar 7, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.59M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $34.36M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $32.15M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $28.15M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $21.96M | Mar 22, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.44M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($41.40M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($52.40M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($34.90M) | Mar 21, 2024 |
| FY2021 | Dec 31, 2021 | ($1.14M) | Mar 7, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $26.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $12.04M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $41.37M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $5.54M | Mar 22, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.22M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $97.84M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $119.48M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $180.79M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $96.70M | Mar 22, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.63M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $47.09M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $52.57M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $53.53M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $36.33M | Mar 22, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.59M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $25.65M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $66.91M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $127.26M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($111.46M) | Mar 21, 2024 |
| FY2021 | Feb 28, 2021 | $0 | Mar 7, 2022 |
| FY2022 | Dec 31, 2020 | ($58.71M) | Mar 22, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($358.57M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($297.13M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($244.34M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($173.29M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($115.08M) | Mar 22, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.42M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $48.28M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $35.93M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $57.62M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $56.03M | Mar 22, 2023 |
| FY2021 | Feb 28, 2021 | $0 | Mar 7, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (16) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (19) | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (16) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (19) | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.88M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 4.83M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 4.57M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 44.06M | Mar 21, 2024 |
| FY2023 | Jun 8, 2022 | 43.37M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 2.97M | Mar 22, 2023 |